L B Bohle to host continuous pharma manufacturing workshops

Published: 3-Sep-2018 Featured companies: LB Bohle
Pharmaceutical

The German manufacturer is hosting a second workshop 18–20 September 2018

The German manufacturer L.B. Bohle is hosting the second workshop on continuous pharmaceutical manufacturing from 18-20 September 2018.

The 3 day hands-on workshop will facilitate all relevant theme complexes for continuous manufacturing:

  • large practical hands-on continuous manufacturing demonstrations on every day
  • industrial insights and case studies
  • insights from work with regulatory bodies
  • academial insights with results from latest research
  • insights and new highlight from vendors

Register now: rates, excl. VAT €985

For further information see the attached programme on the L. B. Bohle website.

Featured companies

L.B. Bohle is a global acting manufacturer for the pharmaceutical industry. The range of products includes process and handling equipment to produce pharmaceutical solids. As a...
See more

You may also like

Manufacturing

L.B. Bohle debuts novel laboratory equipment at ACHEMA 2024

Read more
Visit the company at Hall 3.0, Booth A46/A71 to discover granulators, mixers and coaters

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  5. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations

Relevant companies

See more

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

L.B. Bohle debuts novel laboratory equipment at ACHEMA 2024

Visit the company at Hall 3.0, Booth A46/A71 to discover granulators, mixers and coaters
Digital

L.B. Bohle produces Dry Granulator BRC100 and Filmcoater BFC 100 Containment

Machine manufacturer provides containment solutions for film coating applications and a dry granulation process across two different projects
Manufacturing

Continuous pharmaceutical manufacturing

Ennigerloh took place in September and saw more than 40 experts from Asia, Europe, South and North America at the technical symposium
Manufacturing

Closed-loop control for continuous production

The ability to measure, monitor and control pharmaceutical production throughout the entire process offers significant time and cost benefits
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Distribution

Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01

The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
Subscribe now